Dr. Finn Discusses Palbociclib for Patients With Advanced Breast Cancer

Richard S. Finn, MD
Published: Tuesday, Feb 10, 2015



Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that led to the FDA approval of palbociclib in combination with letrozole as a first-line treatment for patients with ER-positive, HER2-negative, advanced breast cancer.

Early studies showed that ER-positive, HER2-negative breast cancer models seem to be uniquely sensitive to CDK 4/6 inhibition, Finn notes. Additionally, there was a synergistic inhibition of growth of these models when combined with anti-estrogens.

The global, open-label PALOMA-1 study randomized 165 postmenopausal women with ER-positive, HER2-negative breast cancer to palbociclib with letrozole or letrozole alone. The median progression-free survival (PFS) with palbociclib was 20.2 versus 10.2 months for letrozole alone (HR = 0.49; P = .0004).

In addition to the approval, early results from PALOMA-1 culminated in a breakthrough therapy designation for palbociclib. Following the FDA's decision, palbociclib became the first approved CDK 4/6 inhibitor.
 


Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that led to the FDA approval of palbociclib in combination with letrozole as a first-line treatment for patients with ER-positive, HER2-negative, advanced breast cancer.

Early studies showed that ER-positive, HER2-negative breast cancer models seem to be uniquely sensitive to CDK 4/6 inhibition, Finn notes. Additionally, there was a synergistic inhibition of growth of these models when combined with anti-estrogens.

The global, open-label PALOMA-1 study randomized 165 postmenopausal women with ER-positive, HER2-negative breast cancer to palbociclib with letrozole or letrozole alone. The median progression-free survival (PFS) with palbociclib was 20.2 versus 10.2 months for letrozole alone (HR = 0.49; P = .0004).

In addition to the approval, early results from PALOMA-1 culminated in a breakthrough therapy designation for palbociclib. Following the FDA's decision, palbociclib became the first approved CDK 4/6 inhibitor.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x